50 Best Peptides

This website is for informational purposes only and does not constitute medical advice. Read disclaimer

#126

Cholecystokinin (CCK)

GastrointestinalCCKCCK-8CCK-33Pancreozymin

A peptide hormone produced in the duodenum that stimulates gallbladder contraction, pancreatic enzyme secretion, and acts as a satiety signal, with additional roles as a neurotransmitter in the brain.

Share:

Overview

Cholecystokinin (CCK) is a peptide hormone discovered in 1928 by Andrew Ivy and Eric Oldberg, who identified a substance in intestinal extracts that could stimulate gallbladder contraction (hence the name: "cholecysto" = gallbladder, "kinin" = to move). It exists in multiple molecular forms (CCK-8, CCK-22, CCK-33, CCK-58) produced by post-translational processing of a single precursor protein, with CCK-8 being the most potent form.

CCK is primarily synthesized by I-cells in the duodenal and jejunal mucosa in response to the presence of fats and proteins in the small intestinal lumen. It acts through two G-protein coupled receptor subtypes: CCK-A (now CCK-1), primarily found in the gastrointestinal tract, and CCK-B (now CCK-2), predominantly found in the brain. Through CCK-1 receptors, CCK stimulates gallbladder contraction, pancreatic enzyme secretion, and relaxation of the sphincter of Oddi, facilitating the digestion and absorption of dietary fats.

One of CCK's most important physiological roles is as a satiety signal. Released postprandially, CCK acts on vagal afferent neurons to transmit satiety signals to the brain, leading to meal termination. This anorexigenic effect has made CCK receptors targets for anti-obesity drug development, though short-term satiety effects have not consistently translated to sustained weight loss in clinical trials.

In the central nervous system, CCK functions as a neurotransmitter with diverse roles. It is one of the most abundant neuropeptides in the brain, involved in anxiety and panic responses (particularly through CCK-2 receptors), pain modulation, memory, and the regulation of dopamine signaling. CCK-4, a synthetic tetrapeptide fragment, reliably induces panic attacks in human subjects and has been used as a research tool for studying panic disorder. The interaction between CCK and dopamine systems has implications for understanding schizophrenia and addiction.

Research Uses & Applications

  • Diagnostic agent for gallbladder function testing (CCK-stimulated hepatobiliary scintigraphy)
  • Research tool for studying satiety, appetite regulation, and obesity mechanisms
  • CCK-4 used in research to model panic attacks for studying panic disorder
  • Target pathway for drug development in gastrointestinal and appetite disorders
  • Studied for roles in pain modulation and as an anti-opioid peptide
  • Research into CCK's interactions with dopamine systems in addiction and psychiatric disorders

Key Research Findings

  • IV CCK-8 administration consistently reduced meal size and food intake in human subjects, confirming its role as a physiological satiety signal.
  • CCK-stimulated hepatobiliary scintigraphy (HIDA scan) has become a standard diagnostic test for gallbladder dysfunction, with ejection fractions below 35% considered abnormal.
  • CCK-4 administration reliably induced panic attacks in approximately 50-60% of healthy volunteers and over 90% of panic disorder patients in controlled studies.
  • Long-term studies showed tolerance to CCK's satiety effects, limiting its potential as a standalone anti-obesity therapy.
  • Research demonstrated CCK modulates opioid-mediated analgesia, with CCK receptor antagonists potentiating morphine's analgesic effects in animal models.

Risks & Side Effects

  • Exogenous CCK can cause nausea, abdominal cramps, and gallbladder contraction.
  • CCK-4 administration for panic research carries risk of severe anxiety and panic symptoms.
  • Chronic CCK receptor stimulation may promote tolerance to satiety effects.
  • Potential for gallbladder complications with excessive stimulation in patients with gallstones.
  • Not used as a routine therapeutic agent outside of diagnostic imaging applications.

Administration

Diagnostic use: sincalide (synthetic CCK-8 analog) administered IV at 0.02 mcg/kg over 30-60 minutes for gallbladder function testing. Research applications: CCK-8 infused IV at rates of 0.5-2 ng/kg/min for satiety studies; CCK-4 at 25-50 mcg IV bolus for panic induction studies. Not used for chronic therapeutic administration. Available as sincalide (Kinevac) for diagnostic use.

Legal Status

Sincalide (synthetic CCK-8 analog) is FDA-approved as a diagnostic agent for gallbladder function testing. CCK itself is not approved as a therapeutic drug. CCK peptide fragments are available as research reagents. Not a controlled substance.

Frequently Asked Questions

What is Cholecystokinin (CCK)?

A peptide hormone produced in the duodenum that stimulates gallbladder contraction, pancreatic enzyme secretion, and acts as a satiety signal, with additional roles as a neurotransmitter in the brain.

What are the main uses of Cholecystokinin (CCK)?

The primary research applications of Cholecystokinin (CCK) include: Diagnostic agent for gallbladder function testing (CCK-stimulated hepatobiliary scintigraphy); Research tool for studying satiety, appetite regulation, and obesity mechanisms; CCK-4 used in research to model panic attacks for studying panic disorder; Target pathway for drug development in gastrointestinal and appetite disorders; Studied for roles in pain modulation and as an anti-opioid peptide; Research into CCK's interactions with dopamine systems in addiction and psychiatric disorders.

What are the risks and side effects of Cholecystokinin (CCK)?

Documented risks and side effects include: Exogenous CCK can cause nausea, abdominal cramps, and gallbladder contraction.; CCK-4 administration for panic research carries risk of severe anxiety and panic symptoms.; Chronic CCK receptor stimulation may promote tolerance to satiety effects.; Potential for gallbladder complications with excessive stimulation in patients with gallstones.; Not used as a routine therapeutic agent outside of diagnostic imaging applications.. Always consult a healthcare professional before considering any peptide.

Is Cholecystokinin (CCK) legal?

Sincalide (synthetic CCK-8 analog) is FDA-approved as a diagnostic agent for gallbladder function testing. CCK itself is not approved as a therapeutic drug. CCK peptide fragments are available as research reagents. Not a controlled substance.

How is Cholecystokinin (CCK) administered?

Diagnostic use: sincalide (synthetic CCK-8 analog) administered IV at 0.02 mcg/kg over 30-60 minutes for gallbladder function testing. Research applications: CCK-8 infused IV at rates of 0.5-2 ng/kg/min for satiety studies; CCK-4 at 25-50 mcg IV bolus for panic induction studies. Not used for chronic therapeutic administration. Available as sincalide (Kinevac) for diagnostic use.

Related Peptides

Stay Updated on Peptide Research

Get the latest peptide research news and updates delivered to your inbox.

Important Disclaimer

The information on this page is for educational and informational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement. 50 Best Limited does not endorse, recommend, or promote the use of any peptide for self-administration. Read our full disclaimer.